Ashley Ghiaseddin

RNA aggregates harness the danger response for potent cancer immunotherapy

Héctor R. Méndez‐Gómez, Anna DeVries, Paul Castillo et al. · Cell · 2024 · 105 citations · Full text

Cancer Immunosurveillance, Danger Response, Medicine +10

Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma

Ashley Ghiaseddin, David A. Reardon, Woody Massey et al. · The Oncologist · 2017 · 59 citations · Full text

Glioma Immunotherapy: Advances and Challenges for Spinal Cord Gliomas

Clare Grady, Kaitlyn Melnick, Ken Porche et al. · Neurospine · 2022 · 26 citations · Full text

Immunology, Immunotherapeutics, High-grade Gliomas +19

Final analysis of 2-THE-TOP: A phase 2 study of TTFields (Optune) plus pembrolizumab plus maintenance temozolomide (TMZ) in patients with newly diagnosed glioblastoma.

David D. Tran, Ashley Ghiaseddin, Dongjiang Chen et al. · Journal of Clinical Oncology · 2023 · 12 citations

Maintenance Temozolomide, Immunodeficiencies, Immune Regulation +28

Eleven Month Progression–Free Survival on Vemurafenib Monotherapy in a Patient With Recurrent and Metastatic <i>BRAF</i> V600E–Mutated Glioblastoma WHO Grade 4

Kanita Beba Abadal, Meggen Walsh, Anthony T. Yachnis et al. · JCO Precision Oncology · 2017 · 11 citations

Neuro-oncology, Oncology, Cancer Management +8